Skip to content

Effect of Local Cannabidiol on Clinical and Inflammatory Outcomes in Periodontal Maintenance Patients.

Effect of Local Cannabidiol on Clinical and Inflammatory Outcomes in Periodontal Maintenance Patients.

Status
Withdrawn
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05646459
Enrollment
0
Registered
2022-12-12
Start date
2020-05-14
Completion date
2020-05-14
Last updated
2024-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis, Adult, Inflammation Gum

Brief summary

This study will determine if cannabidiol (CBD) has any effect on local inflammation in periodontal maintenance patients. Many successful therapies exist for the active, untreated periodontal patient. Unfortunately, periodontology has not yet discovered a therapy that will predictably treat local inflammation in patients who are at risk for further pocketing, bleeding on probing, bone loss and ultimately, tooth loss. Although CBD has been patented in various forms since the 1940s, its acceptance and availability to patients has only recently expanded. Marketing of CBD to periodontal patients as a means to control inflammation is commonplace online and in CBD-specific shops. In determining if CBD is a successful supplement to conventional periodontal inflammation control therapies, millions of patients could benefit from this treatment.

Detailed description

The purpose of this study is to determine if CBD has any effect on local inflammation in periodontal maintenance patients. This research is significant and innovative as it will act as a pivotal study to determine if CBD is worthy of further study in the area of periodontal disease and it will be a human clinical trial focusing on a specific aspect of periodontal disease, the maintenance patient. Many successful therapies exist for the active, untreated periodontal patient. Unfortunately, periodontology has not yet discovered a therapy that will predictably treat local inflammation in these patients which are at risk for further pocketing, bleeding on probing, bone loss and ultimately, tooth loss. Although CBD has been patented in various forms since the 1940s, its acceptance and availability to patients has only recently expanded exponentially. Marketing of CBD to periodontal patients as a means to control inflammation is already commonplace online and in CBD-specific shops; it is the duty of periodontology to determine the efficacy and success of this known anti-inflammatory compound as it relates to clinical periodontal parameters. To determine if CBD is a successful adjunct to conventional periodontal inflammation control therapies would be a boon to the advancement of oral health and to millions of patients that could benefit from this treatment.

Interventions

DRUGcannabidiol

This group will locally apply cannabidiol to a posterior, localized 6-9 mm bleeding periodontal pocket.

DEVICEfloss

This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).

DEVICEproxabrush

This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).

Sponsors

University of Nebraska
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* diagnosis of chronic moderate-advanced periodontitis * one 6-9 mm interproximal probing depth * overall good systemic health * history of regular PMT

Exclusion criteria

* systemic disease that significantly affect periodontal inflammation and bone turnover * surgical periodontal therapy in the past year * pregnant/breast-feeding females.

Design outcomes

Primary

MeasureTime frameDescription
Clinical Attachment LevelbaselineAmount of epithelial attachment to tooth

Secondary

MeasureTime frameDescription
Inflammatory BiomarkersbaselineIL-1B, IL-10, IL-6

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026